Atlas Trials

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

Clinical trial NCT06343038 · RECRUITING

Trial details

NCT number
NCT06343038
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Castration-resistant Prostate Cancer
Start date
2024-02-20
Primary completion
2028-06-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.